• Pure Extracts Technologies trading on CSE under symbol PULL
• Company runs first oil extraction, distillation under new licenses
• PULL products highly desired by provincial dispensaries as consumers gravitate to FSO

An emerging leader in extraction, Pure Extracts Technologies (CSE: PULL) began trading on the Canadian Securities Exchange (“CSE”) earlier this month under the symbol ‘PULL’. The plant-based extraction Company focuses on cannabis, hemp, and functional mushroom sectors and uses its proprietary CO2 extraction methodology to obtain full-spectrum oil (“FSO”) from cannabis and hemp biomass. “We are pleased to have listed on the Canadian Securities Exchange as a significant first step towards Pure Extracts’ continual expansion within the emerging extraction space,” said Pure Extracts’ CEO Ben Nikolaevsky. “There currently is a tremendous opportunity for growth in consumer natural health products, for which we plan on playing a pivotal role within the supply chain mechanism by providing full spectrum oil products for the cannabis, hemp and functional mushroom space.” In a letter to shareholders, Nikolaevsky called the CSE listing a “major milestone” that gives the Company’s shareholders liquidity in the public markets and the Company access to capital. In that same letter, he noted that Pure Extracts recently received its Standard Processing license from Health Canada. “We have spent the last 6 weeks commissioning our equipment for commercial production,” he said. “On Nov. 4^th, we ran our first oil extraction and distillation under our licences. We are super excited about our first trial run.” Nikolaevsky noted that Pure Extracts was running required samples over the coming weeks to “apply for our Sales license with Health Canada, which will allow us to bring our vape brand, Pure Pulls and our edibles brand, Pure Chews to the consumer market. Our products are highly desired by the provincial dispensaries as consumers are gravitating to full-spectrum oil (‘FSO’), which we specialize in.” “Pure Extracts anticipates starting its extraction tolling business in December with its first batch being scheduled for extraction early in the month”, said Nikolaevsky. In addition, now that the Company can provide samples, it is bidding on several contracts in the white label arena. “Although the Health Canada approval took longer than we planned for, we believe we can capture some meaningful volumes in the white label area into Q1 2021,” he said. In addition, Pure Extracts is entering the functional mushroom space “We intend to launch these products in Q1 from an online portal that we are developing. Functional mushrooms have been identified as the new ‘wonder’ product in the wellness space and have been rapidly growing in popularity, so this is a very exciting move for us,” he noted. Pure Extracts Technologies Inc., headquartered in Pemberton, British Columbia, is a plant-based extraction Company with a new vertical in functional mushrooms. The Company is positioned to be a successful extraction Company and a leader in the rapid development and commercialization of functional mushroom products. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease
• The company plans a complex, multi-armed Phase 2 trial of its candidate Berubicin in hopes that the drug candidate may ultimately gain an expedited pathway to approval and registration from the FDA
• The trial for combatting Glioblastoma Multiforme is expected to begin next year, and on Nov. 12 the company’s officers launched a webinar to provide information on how the trial will be designed
• CNS Pharmaceuticals is also preparing, in partnership with its sub-licensee WPD Pharmaceuticals, for two additional trials of Berubicin to be conducted in Poland including the first-ever Phase 1 pediatric trial as well as a parallel Phase 2 trial in adults

A biopharmaceutical company working to find a better way of treating an aggressive form of brain tumor, Glioblastoma Multiforme (“GBM”), which is currently regarded as incurable and ultimately fatal, announced recently that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review. It includes a novel clinical trial design it hopes will lead to a breakthrough, and on Nov. 12 company officers discussed the design for the upcoming Phase 2 U.S. trial in a webinar open to the public (https://ibn.fm/bV2e2). “I would like to remind everyone that this upcoming Phase 2 trial will build on the success of the Phase 1 trial of Berubicin in which the clinical benefit response was 44 percent, including one patient … who had a durable complete response and is still alive and cancer-free today, 14 years after treatment with Berubicin, and another two patients with partial responses, who had reductions of greater than 25 percent in the size of their tumors,” CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco told the webinar audience. CNS Pharmaceuticals’ lead drug candidate in treating GBM, Berubicin, is an anthracycline. “Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers, including breast, ovarian, lung, lymphoma and leukemia, and other malignancies as well. However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain,” Climaco said. “Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies,” he said. CMO Dr. Sandra Silberman explained that the Phase 2 trial will allow a real-time comparison between Berubicin patients and patients receiving the normal standard of care, using “interim analyses that could impact and in fact reduce the numbers of patients required to establish the effectiveness of Berubicin.” Under the parameters of the trial, 243 patients will participate, 162 of them receiving Berubicin and the other 81 receiving the chemotherapy drug lomustine. About 60 study centers will be used in North America, Europe and the Asia-Pacific region. Once 50 percent of the patients have been in the study for six months, the interim analysis will begin. “We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” Silberman said. The study will also be designed to preserve patient safety even with the continuation of the COVID-19 pandemic and GBM patients who don’t ultimately qualify for the study will be allowed other avenues to try Berubicin under U.S. “right to try” laws. “We now have a drug supply manufactured and will do our best to get these patients that could benefit from Berubicin and have failed standard therapies (to where they) can be part of these parallel studies for which we will continue to accrue safety and efficacy information,” Silberman said. Additional information about such opportunities will be posted on the company’s website. Climaco said the complex trial design is not only the most potentially beneficial for studying Berubicin’s effects, but ultimately the most cost-effective design for the company’s shareholders as well because the Phase I trial not only showed the drug’s potential for safe use, but efficacy also. “Rather than conduct a single-arm trial of Berubicin that would likely simply show us more interesting positive data, we chose to effectively allow our Phase 2 trial to incorporate an arm receiving standard of care such that any significant impact of Berubicin could be better analyzed,” he said. Because the trial is expected to eventually cost $30 million to $35 million, Climaco said the company is taking a phased fund-raising approach over the next two to two and a half years, progressing from one success to the next rather than trying to raise all of the capital at once. Sound results from the Phase 2 trial could potentially sway the FDA to grant Berubicin an expedited pathway to approval, which would save time in the long run. “Which is of course the valuable important commodity here,” he said. CNS Pharmaceuticals is also preparing, in partnership with its sub-licensee WPD Pharmaceuticals, for two additional trials of Berubicin to be conducted in Poland. The first is a first-ever Phase 1 pediatric trial. The secondi s a parallel Phase 2 trial in adults that will be used as additional data to supplement and strengthen the data submitted to the FDA from the primary trial conducted by CNS Pharmaceuticals. CNS Pharmaceuticals is also developing a drug candidate known as WP1244 with a DNA-binding agent that preclinical studies have shown to be 500 times more potent than chemotherapy drug daunorubicin in stopping tumor cell expansion. This drug is undergoing additional pre-clinical studies in preparation for a potential future Phase 1 clinical trial. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Unwined is relaxing, stress-relieving, sleep-promoting beverage that may help with immune support
• New product addresses current needs of valued SHRG distributors and customers
• Elevacity products formulated with proprietary combination of ingredients, dubbed “happiness”

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the health and wellness direct-selling industry, has released a new beverage product (https://ibn.fm/ILKXX). SHRG, through its wholly owned subsidiary, Elevacity(R) U.S. LLC, has unveiled a new beverage: Unwined(TM). The new product is a relaxing, stress-relieving, sleep-promoting beverage that may help with immune support. “Our goal with Unwined was to give consumers something to help them relax after a long or busy day,” said Elevacity CEO Keith Halls. “We are excited to launch this new product category, which addresses the current needs of our valued distributors and customers.” Unwined is a full-bodied, mood-enhancing drink made with a specific blend of antioxidants, adaptogens, extracts and minerals. This blend of ingredients is formulated to help reduce excess cortisol and promote relaxation and sleep. The tasty, berry-flavored wellness beverage is an ideal complement to Elevacity’s already existing products, all designed to provide consumers with the safest, most efficacious offerings to help elevate their lives. Elevacity flagship products — Elevate MAX(TM) coffee, Elevate ZEST(TM), Elevate NITRO(TM) and Choclevate(R) — are meant to be taken in tandem with Elevacity’s XanthoMax(R) D.O.S.E. nutritional supplement. D.O.S.E. — a proprietary combination of four hormones, dubbed “happiness hormones” by the company — includes dopamine, oxytocin, serotonin and endorphins. In addition to beverages and XanthoMax, Elevacity offers a trio of powerful skincare products that include a high-organic mud mask, an active-life facial serum and a timeless eye gel. SHRG is committed to offering its sales force — a powerful group of independent contractors called Elepreneurs — and its customers nonaddictive products that contain natural ingredients. Elevacity wellness products don’t contain additives or fillers. In addition to its extraordinary products, the company is dedicated to re-shaping how entrepreneurs succeed in today’s world. Sharing Services is growing an international network of home-based Elepreneurs that share SHRG products and services designed to elevate the lives of individuals from every walk of life. Sharing Services Global Corporation is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct selling sector and other industries. The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Sharing Services has two primary divisions: Elevacity(R) Holdings LLC, the parent company of Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC, the parent company of wholly owned subsidiary Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line. For more information about this company, please visit www.SHRGInc.com, www.Elevacity.com or www.Elepreneur.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Sales of CBD products through convenience, gas stores grew by 2,276% in 2019.
• CBD drinks, valued at $52 million in c-store sales in 2019, are highly popular among new consumers.
• WTER offers A88CBD(TM) product line including beverages and lab-tested, hemp extract gummies, capsules, salves, balms, lotions and more.

As the use of cannabidiol (“CBD”) becomes more mainstream, convenience stores are in an ideal position to benefit from the product’s rapid growth, according to a recent CBD Retail Trends article (https://ibn.fm/c0E0d). That’s good news for The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), a company with a robust CBD-infused beverage line and a growing distribution network encompassing convenience stores around the country. “While few consumers had heard of CBD prior to 2018, the signing of the farm bill in December 2018 — which removed hemp from the legal definition of marijuana and the Schedule 1 Controlled Substances list — helped usher in exponential growth through extensive media coverage, expanded product availability including in drug stores and pharmacies, and widespread word-of-mouth through social media,” reported the CBD Retail Trends article. “Sales of CBD products through convenience and gas stores grew by 2,276% in 2019 to reach $122 million. “CBD drinks, valued at $52 million in c-store sales in 2019, are highly popular among new consumers and skew younger, with millennials as the largest consumer group,” the article continued. “Demand for CBD-infused drinks remains high despite the Food and Drug Administration (“FDA”) stating that CBD cannot be sold as a dietary supplement or used as a food additive.” Those numbers may be only the tip of the iceberg for CBD potential in the c-store channel. WTER’s high-quality line of A88CBD(TM) represents the company’s commitment to offer industry-leading, hemp-derived CBD products that meet consumers needs and support their daily wellness routines. The A88CBD product line features an exclusive line of CBD-infused beverages as well as an expansive line of lab-tested full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with hemp extract powder packs, oil tinctures, capsules, and gummies. Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. Additionally, in 2020, the company launched its A88CBD Infused line of ingestible and topical products, including its CBD water. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• Clean Power Capital Corp., formerly known as Organic Flower Investments Group, is an investment holding company currently focused on investing and financing companies in the renewable energy market
• The company currently has 10 investments in a variety of sectors, including the legal medical and recreational cannabis market
• The company’s primary investment is PowerTap Hydrogen Fueling Corp., a California-based company in the process of developing large, cost-effective hydrogen fueling infrastructure across North America
• The two companies plan to deploy the hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years
• Hydrogen produced using PowerTap’s proprietary technology is available at an estimated one-third the cost of traditional production methods and can be generated directly at the filling station
• As hydrogen-powered vehicles become increasingly popular due to their reduced emissions, cost efficiency, lower fueling times and longer driving ranges, the hydrogen industry is expected to grow to $140 billion in annual revenue by 2030 and $750 billion by 2050
• Leveraging proprietary technology and an impressive IP portfolio, PowerTap and Clean Power Capital are uniquely positioned to capitalize on the market growth and expansion opportunities in the hydrogen fueling space

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity. Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis. Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq). Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’. PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp. Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable. Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development. PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States. Hydrogen Industry Outlook The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry. Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles. “As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem). A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050. The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report. With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap. “As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added. Management Team Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings. Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario. Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies. Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits. For more information, visit the company’s website at www.CleanPower.Capital. NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• Online gaming industry outperformed both box office, record music industries by more than $100 billion in 2019
• The eSports segment expected to rise from $1 billion in 2019 to $1.7 billion in 2021
• Dozens of revenue streams exist within online gaming industry, each presenting an opportunity to capitalize on everchanging market

The online gaming industry is quickly growing into a multibillion-dollar industry. Even though it began in the 1970s, the space did not enter the mainstream until the 1990s when increasing numbers of people had access to the internet. Since then, the industry has rapidly grown into one of the most profitable industries worldwide. In 2019 it outperformed both the global box office and global recorded music industries by more than $100 billion. Esports makes up one segment of this ecosystem, and Mobius Interactive is ready to capitalize on this segment. To help the company achieve that objective, Mobius has strategically unveiled three diverse gaming brands: Aragon Casino, Club Double, and Mobius.Bet. Aragon Casino and Club Double provide access to more than 4,000 live table games, video poker and slots that can be played via desktop or mobile. Mobius.Bet focuses on eSports, offering an estimated 34 unique games and tournaments. Mobius.Bet is Mobius Interactive’s dedicated eSports hub. It caters to the 18- to 38-year-old eSports community with loyalty programs, targeted gamification and product merchandising. The eSports segment is expected to rise from $1 billion in 2019 to $1.7 billion in 2021. Mobius launched as an online gaming operator in September 2020, but it isn’t entering as a new player. The company’s leadership team brings with it a wealth of experience in the gaming world and in creating successful startups. All one has to do is take a look at the top two players to recognize they aren’t new to the game. CEO Lynn Pearce has more than 15 years of success in the global gaming industry, writes regularly for “Infinity Gaming Magazine” and has been a judge for the International Gaming Awards. Robin Lawson, vice president and COO, is one of the original founders of the eSports.com brand and has been involved in iGaming for more than a decade. Esports may only be a fraction of the $196 billion in revenue the online gaming industry is estimated to reach by 2022, but it’s not the only market that Mobius has entered. There are dozens of revenue streams within the online gaming industry, each presenting an opportunity to capitalize on an evergrowing, everchanging market. In partnership with leading and award-winning eSports and iGaming platform Ultra Play, Mobius Interactive seeks to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance engagement by leveraging state-of-the-art customer relationship management systems and joint ventures with more than 600 VIP and master-gaming affiliates. The possibilities of online gaming are endless, and Mobius has already launched an eSports hub, live Casinos, slots and more. Over 4,000 online games are currently available from this company that launched only a few months ago. One can only imagine what new adventures Mobius has waiting for its gamers. For more information, visit the company’s website at www.MobiusInteractive.ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• MustGrow uses novel plant compounds to develop superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides
• The company leverages its innovative technology platform and the natural defensive mechanisms of the mustard plant for broad use in crop production and protection in order to provide consumers the healthy, safe and natural foods they demand
• The company has EPA approval for the granule form of its flagship product, TerraMG, and is currently waiting to receive approval for the liquid form in the United States and Canada
• MustGrow already has multiple projects in various stages of development, with a focus on all-natural and organic solutions for crops
• The liquid form of TerraMG has the potential for multiple applications, thus significantly enhancing the company’s IP position
• MustGrow is focused on the disruption of the global pesticide market, which totals $65 billion, while testing multiple applications of TerraMG and other products in significant markets
• The company has 37 million shares outstanding; management and advisors own 22%

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, including fruits and vegetables. The company uses novel compounds from the mustard plant to provide superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides. Management & advisors own 22% of the company’s 37 million shares outstanding. Leveraging its innovative platform, MustGrow effectively extracts the natural defense mechanisms of the mustard seed for broad use in crop production and protection. The company uses components of mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests like nematodes. This company’s all-natural, effective, safe and easy-to-use solution is ideal for farmers looking to raise healthy crops without chemical pesticides amid growing concerns worldwide over the negative effects of chemical pesticide solutions. MustGrow, which went public in 2019, was founded in Saskatoon, Canada, and is currently focused on disrupting the $65 billion global pesticide market with its 100% owned and patented mustard-derived technology. Canada produces 28% of the global mustard crop and is the world’s largest exporter, with a 57% market share. TerraMG and Pipeline The company’s technology extracts the mustard plant’s natural organic compounds, which, when combined with water, form Allyl isothiocyanate (AITC) and serve as a natural defense mechanism for the plant against pests and diseases. MustGrow’s mustard-derived technology acts as both a natural bio-pesticide and as a non-selective bio-herbicide. There are currently more than 110 independent third-party trials that confirm the safety and efficacy of MustGrow’s solutions, potentially positioning the company as a leading provider of safe plant protection solutions in a market that is gradually eliminating the use of chemical compounds. MustGrow’s primary product at the moment is the new liquid formulation TerraMG, which has the potential to compete against existing chemistries on both efficacy and price. Its initial target market is as a pre-plant soil bio-pesticide for use with higher-value crops such as fruits and vegetables. This liquid formulation is safe and easy to transport and has already demonstrated its efficacy against several pests and diseases. In addition to its use as a pre-plant soil treatment, TerraMG has significant potential for multiple applications in several other markets, which is expected to aggressively expand the company’s IP portfolio. MustGrow has already confirmed or is in the process of testing multiple applications of TerraMG, including fruit and vegetable soil fumigation ($1.2 billion estimated global market), container fumigation ($2 billion estimated global market), tobacco nematode and disease fumigation ($4 billion estimated global loss), non-selective herbicide ($13 billion estimated global market), food-borne pathogens ($15 billion estimated global market) and more. The company anticipates registration approval for the liquid formulation (TerraMG) as a pre-plant bio-pesticide for soil-borne diseases and pests from the EPA (United States) and PMRA (Canada) in 2021. The company already has EPA and PMRA approval for the product’s granular form. Currently, MustGrow’s pipeline also includes:

• TerraMG, a pre-plant soil bio-pesticide, for:
  • Fruit & Vegetable– currently in Phase 4
  • Turf & Ornamental– currently in Phase 4
  • Tobacco– currently in Phase 4
  • Potatoes– currently in Phase 4
  • Canola– targeting Clubroot Disease – currently in Phase 3: Advanced Development/Field Trials
  • Bananas– targeting Fusarium wilt TR4 – currently in Phase 1: Proof of Concept/Laboratory
  • Pulse Crops– targeting Aphanomyces – currently in Phase 1: Proof of Concept/Laboratory
• Non-Selective Bio-Herbicide– targeting noxious or resistant weeds – currently in Phase 2: Early Development/Greenhouse
• Storage Bio-Pesticide for Bulk Grain, Fresh Produce– targeting toxins, diseases and insects – currently in Phase 1: Proof of Concept/Laboratory
• Storage Bio-Pesticide for Shipping Containers– targeting fungus, invasive pests and diseases – currently in Phase 1: Proof of Concept/Laboratory
• Bio-Pesticide for Foodborne Pathogens– targeting E. coli, salmonella, Listeria, human pathogens, etc. – currently in Phase 1: Proof of Concept/Laboratory

Market Opportunity The protection of crops with synthetic chemical pesticides represents a $65 billion-dollar global market that is expected to grow in the coming years as the global population grows and needs more food. This number doesn’t include bio-pesticide sales, which are projected to increase to $8.5 billion by 2025, with a CAGR of 14.7%. MustGrow, with its natural bio-pesticide, is targeting not only the bio-pesticide market, but also the global synthetic chemical market so as to help replace harmful synthetic pesticides and provide a natural biologic that has the efficacy of controlling pests and disease compared to synthetic chemicals in some instances. Management Team Corey Giasson is the President, CEO and Director of MustGrow. He is an entrepreneur focused on the agriculture, mining, real estate and oil/gas industries, primarily in the Canadian province of Saskatchewan. Giasson is co-founder and director of Legacy Capital Corp. This private equity company focuses on participating in management buyouts of strong, sustainable cash flowing businesses. He has an MBA and B.Sc. in Agriculture Economics from the University of Saskatchewan. Colin Bletsky is COO and Director of MustGrow. He grew up in Eastern Saskatchewan on his family’s third-generation farm, growing canola, wheat and oats. The majority of his time is spent helping other organizations and farmers grow their businesses – locally and globally. Bletsky has a Bachelor of Science in Agriculture from the University of Saskatchewan and executive education from the London School of Business and INSEAD. Todd Lahti is the company’s CFO. He has extensive experience evaluating and managing biotech, agricultural and oil/gas start-up companies by working directly on financing transactions, mergers and acquisitions, business development, corporate strategy, technology transfer and operations setup. Lahti is a Chartered Financial Analyst and a Chartered Professional Accountant. Brad Munro is Chairman of MustGrow. He is the President and CEO of Bittercreek Capital Corp., a private investment and advisory firm. He has extensive corporate finance and investment experience in the natural gas and oil industries, among others. Munro has a Bachelor of Commerce from the University of Saskatchewan. NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Pure Extracts trading on CSE under “PULL” symbol
• Pure Extracts cannabis and hemp industry verticals include toll processing, white labeling and developing its own private label of cannabis products
• Pure Extracts is entering the functional mushroom market
• Company’s CO2 extraction facility complies with European Union GMP standards – intends to seek EU GMP certification for exports to Europe

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, recently announced that the Company’s stock is now trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL”. “Our trading debut on the CSE is another vote of confidence in our ability to effectively meet the needs of consumers focused on receiving cannabis, hemp and functional mushroom products,” said Pure Extracts’ Chief Executive Officer Ben Nikolaevsky (https://ibn.fm/wRim3). Mainstream science is starting to prove what users have known for years – that functional mushrooms and cannabis-based products can help treat symptoms associated with a variety of physical and mental conditions. Pure Extracts is ahead of the curve in leveraging the market for plant-based medicines on a global scale through a strategy focused on product development, facility expansion, license procurement and product marketing. “There currently is tremendous consumer demand for natural health products with the ability to immediately enhance our quality of life,” said Nikolaevsky. “With Health Canada officially granting Pure Extracts a Standard Processing License under the Cannabis Act, this has put us on a path to deliver full-spectrum oil products by the end of Q4, 2020.” Interest in plant medicines has increased in the scientific community in recent years, particularly regarding the anti-inflammatory effects associated with cannabis (https://ibn.fm/7g4vs) and the ability of cannabidiol (“CBD”) to relieve chronic pain associated with a variety of conditions (https://ibn.fm/ZRbn6). Accordingly, Pure Extracts engages in three cannabis/hemp-related verticals that include in-house marketing for their own brands, converting raw biomass into marketable products, and providing white labeling services for brands looking to enter the rapidly growing market. Functional mushrooms – another Pure Extracts vertical – are rapidly emerging in the collective awareness for their ability to combat illness, increase mental cognition and improve digestion. Varieties containing psilocybin, also known as “psychedelic” or “magic” mushrooms”, are currently being studied by prestigious research institutions like UC Berkeley as a possible treatment for depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease and addiction (https://ibn.fm/BNc5a). Therapy options may be available in the near future as FDA approvals for their use in treatment-resistant depression are expected sometime in 2021 (https://ibn.fm/et1aY). If this happens, demand for highly purified, pharma-grade, mushroom extracts has the potential to skyrocket. Based in Pemberton, British Columbia, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020. The Company engages in the cannabis and hemp industry through toll processing, white labeling, and developing its own private label products, in addition to expanding its business to include functional mushrooms. The Company has a fully-built CO2 extraction facility that complies with European Union GMP standards and intends to seek EU GMP certification in order to export its products to jurisdictions within Europe where such products are legal. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Knightscope’s ASRs have completed over one million field hours and are continuing to improve over time based on field experience
• Knightscope designs, engineers, and builds its ASRs in Silicon Valley, continuing to create American jobs in an economy severely impacted by the pandemic
• The company is committed to changing the way public safety and protection are delivered nationwide
• By joining the $39 billion self-storage industry, Knightscope is targeting to become a prominent security provider in the sector, translating into further opportunities for growth

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous robots focused on enhancing U.S. security operations, is committed to helping create peace and maintaining public safety nationwide via the superior technology it develops and deploys. Combining self-driving technology, robotics and artificial intelligence, Knightscope’s Autonomous Security Robots (“ASRs”) provide 24/7/365 security and are currently patrolling five time zones across the United States, assisting in the creation of safer public and private spaces. The company’s ASRs are a means of physical deterrence, patrolling sites autonomously and providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The collected data is available round the clock through the company’s Knightscope Security Operations Center (KSOC), an intuitive interface that also features 360-degree eye-level HD video streaming, facial recognition, people detection, thermal anomaly detection, automatic license plate recognition, and automatic signal detection. In a recent video presentation titled “Knightscope: Peace Through Superior Technology,” CEO William Santana Li explained how Knightscope’s ASRs are changing the way protection is delivered across the United States (https://ibn.fm/dg15A). It is estimated that there are two million police officers and security personnel across the United States for more than 300 million people across the 50 states. Knightscope’s ASRs are helping to bridge the gap, covering more ground with round-the-clock coverage. In addition to patrolling and peacekeeping, the ASRs have already helped law enforcement and security with the arrests of suspects in crimes that range from armed robbery to hit-and-run accidents. More information about the work Knightscope is doing to fight crime is available at www.Knightscope.com/crime. The current ASR product offering from Knightscope currently includes a K1 stationary unit, a K3 indoor machine, and the K5 outdoor machine. Since the K5 outdoor machine’s deployment, the City of Huntington Park Police Department has noted significant changes in their calls for service (down 10%), crime reports (down 46%), arrests (up 27%), and citations (down 68%). The data was compiled from June to December 2018, before deployment, and compared to June to December 2019, after deployment. Since the company’s creation in 2013, several milestones have already been achieved, including:

• Establishing a 15,000-square-foot facility in Mountain View, California, where Knightscope designs, engineers, and builds their proprietary technology;
• Completing more than one million hours in the field, securing contracts across five United States’ time zones; and
• Continuing to hire and navigate the global pandemic without interruptions, despite the current economic and societal disruptions.

Furthering its position in the industry, Knightscope recently signed an agreement with a Southern California storage facility to utilize the company’s ASR technology. Storage units are particularly susceptible to theft and vandalization. Entry into this $39 billion a year industry offers Knightscope tremendous potential for growth (https://ibn.fm/9S9BC). The long-term vision of Knightscope is to keep an eye on the greater good. The company’s mission is to make the United States of America the safest nation, supporting millions of law enforcement and security personnel across the country. For more information, visit the company’s website at www.Knightscope.com.    Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button in the lower right corner (it is not a bot) for direct contact with CEO.  NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• BRSF announce partnership with Dalmore Group
• New product launch presents solution for growing need for rapid EEG testing due to COVID-19 pandemic
• Brain Scientific shose to extend proposed Reg A+ offering to attract additional investors

Brain Scientific (BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, has announced a partnership with the Dalmore Group in a recent press release (https://ibn.fm/clcDx). “We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states.” The Dalmore Group is a member of FINRA and SIPC with an active presence in the Regulation A+ equity funding space. As one of the most active broker-dealers in the world, the company has served as broker-dealer on more than 50 RegA+ offerings in the past 12 months alone. In 2019 the Dalmore Group raised over $1 billion of capital. The majority of Dalmore Group’s clients come by referral from securities attorneys and industry participants. BRSF is looking to the Dalmore Group for its expert strategic advice and innovative solutions. The Dalmore Group prides itself on understanding a client’s critical business processes and financial goals in order to provide the most comprehensive services possible. Brain Scientific recently launched the next-gen, 19-channel NeuroCap(TM) device. This is a hospitable-grade disposable EEG headset that presents a solution for the growing need for rapid EEG testing due to the COVID-19 pandemic. Through the use of a special adapter, the NeuroCap is compatible with any other amplifiers of EEG signals. Two of the biggest challenges of administering EEGs is the need to measure a patient’s head and the time needed to place the electrodes accurately. This required a specialized neurological technician. The pre-gelled fixed electrode locations, in accordance with the International 10-20 System, allow the NeuroCap to be administered by any healthcare worker making it more accessible to a larger group of patients. The ease of use opens the device up for application in hospitals, clinics and rural areas where medical resources may be limited. Also, the global pandemic is still raging, and new studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing (https://ibn.fm/qRf8w). “With our recent product development and new product launches,” said Goldstein, “we feel the need to extend the proposed Regulation A+ Offering to attract additional investors, which we believe we can better accomplish by working with Dalmore.” For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF